These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 38091179

  • 1. High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.
    Topkan E, Kucuk A, Ozkan EE, Ozturk D, Besen AA, Mertsoylu H, Pehlivan B, Selek U.
    Discov Oncol; 2023 Dec 13; 14(1):230. PubMed ID: 38091179
    [Abstract] [Full Text] [Related]

  • 2. Low Pre-ChemoradiotherapyPan-Immune-Inflammation Value (PIV) Measures Predict Better Survival Outcomes in Locally Advanced Pancreatic Adenocarcinomas.
    Topkan E, Selek U, Kucuk A, Pehlivan B.
    J Inflamm Res; 2022 Dec 13; 15():5413-5423. PubMed ID: 36158517
    [Abstract] [Full Text] [Related]

  • 3. Prognostic Value of Pre-Chemoradiotherapy Pan-Immune-Inflammation Value (PIV) in Locally Advanced Nasopharyngeal Cancers.
    Topkan E, Selek U, Ozturk D, Şenyürek Ş, Kılıç Durankuş N.
    Cancer Control; 2024 Dec 13; 31():10732748241290746. PubMed ID: 39361825
    [Abstract] [Full Text] [Related]

  • 4. A high pan-immune-inflammation value before chemoradiotherapy indicates poor outcomes in patients with small-cell lung cancer.
    Kucuk A, Topkan E, Ozkan EE, Ozturk D, Pehlivan B, Selek U.
    Int J Immunopathol Pharmacol; 2023 Dec 13; 37():3946320231187759. PubMed ID: 37404137
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Value of Novel CARWL Score in Stage IIIC Non-Small-Cell Lung Cancer Patients Undergoing Concurrent Chemoradiotherapy.
    Topkan E, Kucuk A, Ozturk D, Ozkan EE, Besen AA, Pehlivan B, Selek U.
    Can Respir J; 2024 Dec 13; 2024():2803044. PubMed ID: 38975012
    [Abstract] [Full Text] [Related]

  • 6. Pretreatment Pan-Immune-Inflammation Value Efficiently Predicts Survival Outcomes in Glioblastoma Multiforme Patients Receiving Radiotherapy and Temozolomide.
    Topkan E, Kucuk A, Selek U.
    J Immunol Res; 2022 Dec 13; 2022():1346094. PubMed ID: 36479136
    [Abstract] [Full Text] [Related]

  • 7. The Prognostic Value of the Novel Global Immune-Nutrition-Inflammation Index (GINI) in Stage IIIC Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy.
    Topkan E, Selek U, Pehlivan B, Kucuk A, Ozturk D, Ozdemir BS, Besen AA, Mertsoylu H.
    Cancers (Basel); 2023 Sep 11; 15(18):. PubMed ID: 37760482
    [Abstract] [Full Text] [Related]

  • 8. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy.
    Ozdemir Y, Topkan E, Mertsoylu H, Selek U.
    Cancer Manag Res; 2020 Sep 11; 12():1959-1967. PubMed ID: 32214853
    [Abstract] [Full Text] [Related]

  • 9. Pan-immune-inflammation value: a new prognostic index in epithelial ovarian cancer.
    Liao W, Li J, Feng W, Kong W, Shen Y, Chen Z, Yang H.
    BMC Cancer; 2024 Aug 26; 24(1):1052. PubMed ID: 39187781
    [Abstract] [Full Text] [Related]

  • 10. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy.
    Topkan E, Mertsoylu H, Ozdemir Y, Sezer A, Kucuk A, Besen AA, Ozyilkan O, Selek U.
    Cancer Manag Res; 2019 Aug 26; 11():8807-8815. PubMed ID: 31632140
    [Abstract] [Full Text] [Related]

  • 11. Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.
    Chen Y, Gong L, Gu P, Hua Y, Sun Y, Ni S, Zhou X, Tang Z.
    BMC Cancer; 2023 Oct 06; 23(1):944. PubMed ID: 37803437
    [Abstract] [Full Text] [Related]

  • 12. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T, Zhang H, Zhao Y, Li Y, Wang G, Zhang Y, Guo D, Ji S, Sun Z.
    Future Oncol; 2021 Jun 06; 17(17):2141-2149. PubMed ID: 33635094
    [Abstract] [Full Text] [Related]

  • 13. The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor.
    Chen X, Hong X, Chen G, Xue J, Huang J, Wang F, Ali WADS, Li J, Zhang L.
    Transl Oncol; 2022 Mar 06; 17():101338. PubMed ID: 34999541
    [Abstract] [Full Text] [Related]

  • 14. Utility of pre-chemoradiotherapy Pan-Immune-Inflammation-Value for predicting the osteoradionecrosis rates in locally advanced nasopharyngeal cancers.
    Yilmaz B, Somay E, Topkan E, Kucuk A, Pehlivan B, Selek U.
    Strahlenther Onkol; 2023 Oct 06; 199(10):910-921. PubMed ID: 37566126
    [Abstract] [Full Text] [Related]

  • 15. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R, Liu F, Fang C, Yang J, Luo L, Yue P, Gao B, Dong Y, Xiang Y.
    Front Immunol; 2021 Oct 06; 12():724443. PubMed ID: 34777341
    [Abstract] [Full Text] [Related]

  • 16. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients.
    Topkan E, Ozdemir Y, Kucuk A, Besen AA, Mertsoylu H, Sezer A, Selek U.
    PLoS One; 2019 Oct 06; 14(7):e0218627. PubMed ID: 31329602
    [Abstract] [Full Text] [Related]

  • 17. Worth of pan-immune-inflammation value in trismus prediction after concurrent chemoradiotherapy for nasopharyngeal carcinomas.
    Somay E, Yilmaz B, Topkan E, Ozdemir BS, Ozturk D, Besen AA, Mertsoylu H, Selek U.
    Int J Biol Markers; 2024 Mar 06; 39(1):80-88. PubMed ID: 38192114
    [Abstract] [Full Text] [Related]

  • 18. Role of Laparotomy-based Parameters in Assessment of Optimal Primary Debulking Surgery and Long-term Outcomes in Patients with Stage IIIC Epithelial Ovarian Cancer.
    Zhou M, Wang D, Long Z, Zhang Y, Liu J.
    J Cancer; 2020 Mar 06; 11(4):983-989. PubMed ID: 31949501
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis.
    Topkan E, Selek U, Kucuk A, Haksoyler V, Ozdemir Y, Sezen D, Mertsoylu H, Besen AA, Bolukbasi Y, Ozyilkan O, Pehlivan B.
    J Oncol; 2021 Mar 06; 2021():6688138. PubMed ID: 33552158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.